The FDA recently issued a request for information (RFI) describing approaches the agency is considering for the design of early-phase clinical trials of ibogaine drug products and seeking public input on those approaches.
Ibogaine is a psychedelic substance derived from the root bark of the iboga shrub from Central Africa. This RFI marks the latest FDA action to advance an April 2026 executive order on Accelerating Medical Treatments for Serious Mental Illness, which directed agencies to accelerate research into psychedelic medicine.
This recent action signifies that federal gears are continuing to turn on the regulation of psychedelics, especially considering other recent updates, such as a report from SAMHSA, which recommended that states plan for the legal implications of FDA-approved psychedelics, as well as another FDA stakeholder meeting for psychedelics, which was held in September, and the announcement in August by the VA that psychedelic clinical trials were underway, in cooperation with the FDA.
The ibogaine public comment period ended on November 20th, during which stakeholders were encouraged to submit comments electronically. Multiple organizations, thought leaders, and individuals submitted information in response to the FDA’s requests.
The FDA’s RFI had sought comments, data, and information on specific protocol elements relevant to ibogaine drug development, including dose selection and escalation, care setting, safety monitoring, eligibility criteria, stopping rules and safety oversight.
The FDA sought comments, data, and information in four primary areas:
- General study design
- Dose selection and escalation
- Safety considerations
- Ethical and oversight considerations
The information received through this RFI may now help the agency better understand the potential uses, benefits and risks of ibogaine drug products and inform approaches to drug development.





